SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Although the metastasic breast cancer is still an incurable disease, recent advances have increased signifcantly the time to progression and the overall survival. However, too much information has been produced in the last 2 years, so a well-based guideline is a valuable document in treatment decisi...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/156029 |
| Acceso en línea: | https://hdl.handle.net/11441/156029 https://doi.org/10.1007/s12094-018-02010-w |
| Access Level: | acceso abierto |
| Palabra clave: | Advanced Loco-regional recurrence Breast cancer SEOM Guidelines |
| Sumario: | Although the metastasic breast cancer is still an incurable disease, recent advances have increased signifcantly the time to progression and the overall survival. However, too much information has been produced in the last 2 years, so a well-based guideline is a valuable document in treatment decision making. The SEOM guidelines are intended to make evidence-based recommendations on how to manage patients with advanced and recurrent breast cancer to achieve the best patient outcomes based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the United States Preventive Services Task Force guidelines methodology was selected as reference. |
|---|